Analogues of luteinising hormone releasing hormone (LHRH) have recently been introduced as an alternative to surgical orchidectomy in prostate cancer, but there has been concern about the economic costs of long-term treatment.
The paper presents a comparison of costs for LHRH analogues versus orchidectomy in patients treated with orchidectomy in Stockholm County, Sweden, during 1981-86.
Estimates of costs for treatment with a depot LHRH analogue was based on observed treatment times among patients with symptomatic prostate cancer in a British randomised clinical trial of medical castration versus surgical orchidectomy.
Mots-clés Pascal : Tumeur maligne, Prostate, Anticancéreux, Gonadotrophine RH, Facteur libération hormonale, Hormone hypothalamique, Chimiothérapie, Traitement, Analogue, Orchidectomie, Chirurgie, Analyse coût efficacité, Economie santé, Prostate pathologie, Appareil urinaire pathologie, Appareil génital mâle pathologie, Suède, Europe, Homme
Mots-clés Pascal anglais : Malignant tumor, Prostate, Antineoplastic agent, Gonadotropin RH, Hormone releasing factor, Hypothalamic hormone, Chemotherapy, Treatment, Analog, Orchidectomy, Surgery, Cost efficiency analysis, Health economy, Prostatic disease, Urinary system disease, Male genital diseases, Sweden, Europe, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 92-0458402
Code Inist : 002B02R02. Création : 199406.